Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 244

1.

Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).

Antelo G, Mangaonkar AA, Coltro G, Buradkar A, Lasho TL, Finke C, Carr R, Binder M, Gangat N, Al-Kali A, Elliott MA, King RL, Howard M, Melody ME, Hogan W, Litzow MR, Tefferi A, Fernandez-Zapico ME, Komrokji R, Patnaik MM.

Br J Haematol. 2020 Mar 3. doi: 10.1111/bjh.16515. [Epub ahead of print] No abstract available.

PMID:
32128785
2.

Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms.

DiFilippo EC, Coltro G, Carr RM, Mangaonkar AA, Binder M, Khan SP, Rodriguez V, Gangat N, Wolanskyj A, Pruthi RK, Chen D, He R, Viswanatha DS, Lasho T, Finke C, Tefferi A, Pardanani A, Patnaik MM.

Leukemia. 2020 Feb 14. doi: 10.1038/s41375-020-0752-x. [Epub ahead of print] No abstract available.

PMID:
32060405
3.

Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera.

Tefferi A, Guglielmelli P, Lasho TL, Coltro G, Finke CM, Loscocco GG, Sordi B, Szuber N, Rotunno G, Pacilli A, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Vannucchi AM.

Br J Haematol. 2020 Jan 16. doi: 10.1111/bjh.16380. [Epub ahead of print]

PMID:
31945802
4.

Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients.

Coltro G, Antelo G, Lasho TL, Finke CM, Pardanani A, Gangat N, Carr RM, Binder M, Mangaonkar AA, Ketterling R, Fernandez-Zapico ME, Robertson KD, Bosi A, Vannucchi AM, Tefferi A, Patnaik MM.

Am J Hematol. 2020 Jan 10. doi: 10.1002/ajh.25721. [Epub ahead of print] No abstract available.

PMID:
31925810
5.

Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients.

Coltro G, Mangaonkar AA, Lasho TL, Finke CM, Pophali P, Carr R, Gangat N, Binder M, Pardanani A, Fernandez-Zapico M, Robertson KD, Bosi A, Droin N, Vannucchi AM, Tefferi A, Hunter A, Padron E, Solary E, Patnaik MM.

Leukemia. 2019 Dec 13. doi: 10.1038/s41375-019-0690-7. [Epub ahead of print]

PMID:
31836856
6.

Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms.

Tischer A, Antelo G, Coltro G, Finke CM, Gonsalves W, Pardanani A, Ketterling R, Mangaonkar A, Gangat N, Tefferi A, Patnaik MM, Lasho TL.

Leuk Res. 2019 Dec;87:106264. doi: 10.1016/j.leukres.2019.106264. Epub 2019 Oct 24. No abstract available.

PMID:
31706195
7.

Normal gut microbiome in NMDA receptor encephalitis.

Herken J, Bang C, Rühlemann MC, Finke C, Klag J, Franke A, Prüss H.

Neurol Neuroimmunol Neuroinflamm. 2019 Oct 17;6(6). pii: e632. doi: 10.1212/NXI.0000000000000632. Print 2019 Nov.

8.

Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients.

Mangaonkar AA, Swoboda DM, Coltro G, Lasho TL, Novotny PJ, Pophali P, Carr RM, Binder M, Finke CM, Gangat N, Al-Kali A, Begna KH, Reichard KK, Ketterling RP, Al Ali NH, Vafaii P, Zhang L, Padron E, Talati C, Patnaik MM.

Leukemia. 2020 Feb;34(2):656-661. doi: 10.1038/s41375-019-0574-x. Epub 2019 Sep 11. No abstract available.

PMID:
31511613
9.

Disentangling Hippocampal and Amygdala Contribution to Human Anxiety-Like Behavior.

Bach DR, Hoffmann M, Finke C, Hurlemann R, Ploner CJ.

J Neurosci. 2019 Oct 23;39(43):8517-8526. doi: 10.1523/JNEUROSCI.0412-19.2019. Epub 2019 Sep 9.

10.

Computerized Cognitive Training in Multiple Sclerosis: A Systematic Review and Meta-analysis.

Lampit A, Heine J, Finke C, Barnett MH, Valenzuela M, Wolf A, Leung IHK, Hill NTM.

Neurorehabil Neural Repair. 2019 Sep;33(9):695-706. doi: 10.1177/1545968319860490. Epub 2019 Jul 22.

PMID:
31328637
11.

Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.

Coltro G, Lasho TL, Finke CM, Gangat N, Pardanani A, Tefferi A, Jevremovic D, Altman JK, Patnaik MM.

Am J Hematol. 2019 Sep;94(9):E231-E234. doi: 10.1002/ajh.25552. Epub 2019 Jun 14. No abstract available.

PMID:
31173385
12.

Evaluation of the 3D fractal dimension as a marker of structural brain complexity in multiple-acquisition MRI.

Krohn S, Froeling M, Leemans A, Ostwald D, Villoslada P, Finke C, Esteban FJ.

Hum Brain Mapp. 2019 Aug 1;40(11):3299-3320. doi: 10.1002/hbm.24599. Epub 2019 May 15.

PMID:
31090254
13.

Standardization of T1w/T2w Ratio Improves Detection of Tissue Damage in Multiple Sclerosis.

Cooper G, Finke C, Chien C, Brandt AU, Asseyer S, Ruprecht K, Bellmann-Strobl J, Paul F, Scheel M.

Front Neurol. 2019 Apr 9;10:334. doi: 10.3389/fneur.2019.00334. eCollection 2019.

14.

Integrating across memory episodes: Developmental trends.

Shing YL, Finke C, Hoffmann M, Pajkert A, Heekeren HR, Ploner CJ.

PLoS One. 2019 Apr 22;14(4):e0215848. doi: 10.1371/journal.pone.0215848. eCollection 2019.

15.

Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients.

Coston T, Pophali P, Vallapureddy R, Lasho TL, Finke CM, Ketterling RP, Carr R, Binder M, Mangaonkar AA, Gangat N, Al-Kali A, Litzow M, Zblewski D, Pardanani A, Tefferi A, Patnaik MM.

Am J Hematol. 2019 Jul;94(7):767-779. doi: 10.1002/ajh.25488. Epub 2019 May 3.

PMID:
30964202
16.

Childhood multiple sclerosis is associated with reduced brain volumes at first clinical presentation and brain growth failure.

Bartels F, Nobis K, Cooper G, Wendel E, Cleaveland R, Bajer-Kornek B, Blaschek A, Schimmel M, Blankenburg M, Baumann M, Karenfort M, Finke C, Rostásy K.

Mult Scler. 2019 Jun;25(7):927-936. doi: 10.1177/1352458519829698. Epub 2019 Apr 4.

PMID:
30945587
17.

Neuronal autoantibodies associated with cognitive impairment in melanoma patients.

Bartels F, Strönisch T, Farmer K, Rentzsch K, Kiecker F, Finke C.

Ann Oncol. 2019 May 1;30(5):823-829. doi: 10.1093/annonc/mdz083.

18.

3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups.

Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, Finke C, Begna KH, Elliott MA, Hook CC, Wolanskyj AP, Patnaik MM, Hanson CA, Ketterling RP, Sirhan S, Pardanani A, Gangat N, Busque L, Tefferi A.

Mayo Clin Proc. 2019 Apr;94(4):599-610. doi: 10.1016/j.mayocp.2018.08.022. Epub 2019 Feb 26.

PMID:
30824279
19.

Musical memory and hippocampus revisited: Evidence from a musical layperson with highly selective hippocampal damage.

Esfahani-Bayerl N, Finke C, Kopp U, Moon DU, Ploner CJ.

Cortex. 2019 Oct;119:519-527. doi: 10.1016/j.cortex.2018.12.023. Epub 2019 Jan 29.

PMID:
30795831
20.

A transdiagnostic pattern of psychiatric symptoms in autoimmune encephalitis.

Finke C.

Lancet Psychiatry. 2019 Mar;6(3):191-193. doi: 10.1016/S2215-0366(19)30038-0. Epub 2019 Feb 11. No abstract available.

21.

Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model.

Vallapureddy RR, Mudireddy M, Penna D, Lasho TL, Finke CM, Hanson CA, Ketterling RP, Begna KH, Gangat N, Pardanani A, Tefferi A.

Blood Cancer J. 2019 Jan 25;9(2):12. doi: 10.1038/s41408-019-0175-y.

22.

A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy.

Gangat N, Phelps A, Lasho TL, Finke CM, Vallapureddy R, Hanson CA, Ketterling RP, Patnaik MM, Pardanani A, Tefferi A.

Blood Cancer J. 2019 Jan 24;9(2):11. doi: 10.1038/s41408-018-0167-3. No abstract available.

23.

Hippocampal Dentate Gyrus Atrophy Predicts Pattern Separation Impairment in Patients with LGI1 Encephalitis.

Hanert A, Rave J, Granert O, Ziegler M, Pedersen A, Born J, Finke C, Bartsch T.

Neuroscience. 2019 Feb 21;400:120-131. doi: 10.1016/j.neuroscience.2018.12.046. Epub 2019 Jan 6.

PMID:
30625332
24.

Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation.

Patnaik MM, Pophali PA, Lasho TL, Finke CM, Horna P, Ketterling RP, Gangat N, Mangaonkar AA, Pardanani A, Tefferi A.

Haematologica. 2019 Jun;104(6):e236-e239. doi: 10.3324/haematol.2018.208082. Epub 2019 Jan 3. No abstract available.

25.

20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients.

Penna D, Lasho TL, Finke CM, Vallapureddy RR, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Am J Hematol. 2019 Mar;94(3):286-290. doi: 10.1002/ajh.25351. Epub 2018 Dec 5.

26.

The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis.

Tefferi A, Lasho TL, Mudireddy M, Finke CM, Hanson CA, Ketterling RP, Gangat N, Pardanani A.

Am J Hematol. 2019 Mar;94(3):299-305. doi: 10.1002/ajh.25349. Epub 2018 Dec 5.

27.

MPL-mutated essential thrombocythemia: a morphologic reappraisal.

Szuber N, Hanson CA, Lasho TL, Finke C, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Blood Cancer J. 2018 Nov 20;8(12):121. doi: 10.1038/s41408-018-0159-3. No abstract available.

28.

Genetic predictors of response to specific drugs in primary myelofibrosis.

Penna D, Szuber N, Lasho TL, Finke CM, Vallapureddy RR, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Blood Cancer J. 2018 Nov 19;8(12):120. doi: 10.1038/s41408-018-0158-4. No abstract available.

29.

Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates.

Szuber N, Lavu S, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Blood Cancer J. 2018 Nov 19;8(12):118. doi: 10.1038/s41408-018-0157-5. No abstract available.

30.

Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis.

Szuber N, Lasho TL, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Leukemia. 2019 Mar;33(3):780-785. doi: 10.1038/s41375-018-0283-x. Epub 2018 Oct 12. No abstract available.

PMID:
30315236
31.

MRI Findings Suggestive of Herpes Simplex Encephalitis in Patients with Anti-NMDA Receptor Encephalitis.

Scheel M, Finke C.

AJNR Am J Neuroradiol. 2018 Nov;39(11):E120. doi: 10.3174/ajnr.A5788. Epub 2018 Sep 13. No abstract available.

32.

Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms.

Patnaik MM, Lasho T, Howard M, Finke C, Ketterling RL, Al-Kali A, Pardanani A, Droin N, Gangat N, Tefferi A, Solary E.

Blood Cancer J. 2018 Aug 22;8(9):82. doi: 10.1038/s41408-018-0120-5. No abstract available.

33.

Anti-ARHGAP26 Autoantibodies Are Associated With Isolated Cognitive Impairment.

Bartels F, Prüss H, Finke C.

Front Neurol. 2018 Aug 10;9:656. doi: 10.3389/fneur.2018.00656. eCollection 2018.

34.

Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger.

Szuber N, Vallapureddy RR, Penna D, Lasho TL, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Am J Hematol. 2018 Dec;93(12):1474-1484. doi: 10.1002/ajh.25270. Epub 2018 Sep 27.

35.

Mutations and karyotype predict treatment response in myelodysplastic syndromes.

Idossa D, Lasho TL, Finke CM, Ketterling RP, Patnaik MM, Pardanani A, Gangat N, Tefferi A.

Am J Hematol. 2018 Nov;93(11):1420-1426. doi: 10.1002/ajh.25267. Epub 2018 Sep 30.

36.

Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients.

Pophali P, Horna P, Lasho TL, Finke CM, Ketterling RP, Gangat N, Nagorney D, Tefferi A, Patnaik MM.

Am J Hematol. 2018 Nov;93(11):1347-1357. doi: 10.1002/ajh.25246. Epub 2018 Oct 5.

37.

Selective vs stepwise removal of deep carious lesions in primary molars: 12-Months results of a randomized controlled pilot trial.

Elhennawy K, Finke C, Paris S, Reda S, Jost-Brinkmann PG, Schwendicke F.

J Dent. 2018 Oct;77:72-77. doi: 10.1016/j.jdent.2018.07.011. Epub 2018 Jul 17.

PMID:
30025748
38.

Early thrombotic events and preemptive systemic anticoagulation following splenectomy for myelofibrosis.

Mudireddy M, Gangat N, Lasho TL, Finke C, Hanson CA, Ketterling RP, Ashrani AA, Pardanani A, Nagorney DM, Tefferi A.

Am J Hematol. 2018 Sep;93(9):E235-E238. doi: 10.1002/ajh.25203. Epub 2018 Aug 31. No abstract available.

39.

Beyond the limbic system: disruption and functional compensation of large-scale brain networks in patients with anti-LGI1 encephalitis.

Heine J, Prüss H, Kopp UA, Wegner F, Then Bergh F, Münte T, Wandinger KP, Paul F, Bartsch T, Finke C.

J Neurol Neurosurg Psychiatry. 2018 Nov;89(11):1191-1199. doi: 10.1136/jnnp-2017-317780. Epub 2018 Jun 9.

PMID:
29886429
40.

Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information.

Tefferi A, Gangat N, Mudireddy M, Lasho TL, Finke C, Begna KH, Elliott MA, Al-Kali A, Litzow MR, Hook CC, Wolanskyj AP, Hogan WJ, Patnaik MM, Pardanani A, Zblewski DL, He R, Viswanatha D, Hanson CA, Ketterling RP, Tang JL, Chou WC, Lin CC, Tsai CH, Tien HF, Hou HA.

Mayo Clin Proc. 2018 Oct;93(10):1363-1374. doi: 10.1016/j.mayocp.2018.04.013. Epub 2018 Jun 14.

PMID:
29866419
41.

A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone.

Patnaik MM, Rangit Vallapureddy, Lasho TL, Hoversten KP, Finke CM, Ketterling RP, Hanson CA, Gangat N, Tefferi A, Pardanani A.

Leukemia. 2018 Aug;32(8):1850-1856. doi: 10.1038/s41375-018-0121-1. Epub 2018 Apr 2. No abstract available.

PMID:
29712989
42.

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis.

Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Begna KH, Naseema Gangat, Pardanani A, Vannucchi AM.

Leukemia. 2018 Jul;32(7):1631-1642. doi: 10.1038/s41375-018-0107-z. Epub 2018 Mar 23.

43.

Diagnosing MRI-negative autoimmune diseases.

Finke C.

Neurol Neuroimmunol Neuroinflamm. 2018 Apr 2;5(3):e457. doi: 10.1212/NXI.0000000000000457. eCollection 2018 May. No abstract available.

44.

Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates.

Hoversten K, Vallapureddy R, Lasho T, Finke C, Ketterling R, Hanson C, Gangat N, Tefferi A, Patnaik MM.

Leuk Lymphoma. 2018 Dec;59(12):2998-3001. doi: 10.1080/10428194.2018.1452212. Epub 2018 Mar 27. No abstract available.

45.

U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions.

Tefferi A, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Gangat N, Pardanani A.

Leukemia. 2018 Oct;32(10):2274-2278. doi: 10.1038/s41375-018-0078-0. Epub 2018 Feb 27. No abstract available.

46.

Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms.

Lasho TL, Vallapureddy R, Finke CM, Mangaonkar A, Gangat N, Ketterling R, Tefferi A, Patnaik MM.

Blood Cancer J. 2018 Mar 12;8(3):32. doi: 10.1038/s41408-018-0057-8. No abstract available.

47.

U2AF1 mutation variants in myelodysplastic syndromes and their clinical correlates.

Tefferi A, Mudireddy M, Finke CM, Nicolosi M, Lasho TL, Hanson CA, Patnaik MM, Pardanani A, Gangat N.

Am J Hematol. 2018 Jun;93(6):E146-E148. doi: 10.1002/ajh.25084. Epub 2018 Apr 6. No abstract available.

48.

Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.

Lasho TL, Mudireddy M, Finke CM, Hanson CA, Ketterling RP, Szuber N, Begna KH, Patnaik MM, Gangat N, Pardanani A, Tefferi A.

Blood Adv. 2018 Feb 27;2(4):370-380. doi: 10.1182/bloodadvances.2018015875.

49.

Multiple sclerosis-related fatigue: Altered resting-state functional connectivity of the ventral striatum and dorsolateral prefrontal cortex.

Jaeger S, Paul F, Scheel M, Brandt A, Heine J, Pach D, Witt CM, Bellmann-Strobl J, Finke C.

Mult Scler. 2019 Apr;25(4):554-564. doi: 10.1177/1352458518758911. Epub 2018 Feb 21.

50.

CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival.

Szuber N, Finke CM, Lasho TL, Elliott MA, Hanson CA, Pardanani A, Tefferi A.

Blood Cancer J. 2018 Feb 15;8(2):21. doi: 10.1038/s41408-018-0058-7. No abstract available.

Supplemental Content

Support Center